Nasdaq · CIK 0001728328
INM InMed Pharmaceuticals Inc.
Insider trading from SEC Form 4. Last filing 4 d ago. Close $1.36 on Oct 9, 2026, +121% from the 52-week low and -42% from the high.
Last 90 days
Net insider value
+$190k
more bought than sold
Buys
3
$190k by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
INMOct 9, 2026 · close 1.36
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at InMed Pharmaceuticals Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 12Weak | ADAR1 Capital Management, LLC owner buy | $14k 10,903 shares | +1% | - | |
| 19Weak | ADAR1 Capital Management, LLC owner buy | $57k 42,920 shares | +5% | - | |
| 20Weak | ADAR1 Capital Management, LLC owner buy | $118k 91,101 shares | +11% | - |
Transactions
The last 21 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Sharesindirect: See Footnote | +5,601 | $1.33 | $7,436 | 940,622 | 4 d ago |
| Oct 7, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Sharesindirect: See Footnote | +3,046 | $1.33 | $4,051 | 943,668 | 4 d ago |
| Oct 8, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Sharesindirect: See Footnote | +2,256 | $1.33 | $2,997 | 945,924 | 4 d ago |
| Oct 1, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Sharesindirect: See Footnote | +16,431 | $1.33 | $22k | 908,532 | 7 d ago |
| Oct 2, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Sharesindirect: See Footnote | +8,307 | $1.33 | $11k | 916,839 | 7 d ago |
| Oct 5, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Sharesindirect: See Footnote | +18,182 | $1.33 | $24k | 935,021 | 7 d ago |
| Sep 14, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Sharesindirect: See Footnote | +28,505 | $1.29 | $37k | 829,505 | 26 d ago |
| Sep 15, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Sharesindirect: See Footnote | +54,256 | $1.30 | $70k | 883,761 | 26 d ago |
| Sep 16, 2026 | ADAR1 Capital Management, LLC owner | POpen-market purchase Common Sharesindirect: See Footnote | +8,340 | $1.29 | $11k | 892,101 | 26 d ago |
| Dec 19, 2025 | Eric A Adams President & CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +35,000 | $0.00 | $0 | 49,050 | Dec 19, 2025 |
| Dec 15, 2025 | Eric A Adams President & CEO | HExpiration of long derivative Employee Stock Option (Expiration)derivative | -250 | $0.00 | $0 | 14,050 | Dec 17, 2025 |
| Jan 11, 2025 | Andrew Hull director | HExpiration of long derivative Employee Stock Option (Expiration)derivative | -2 | $0.00 | $0 | 975 | Feb 3, 2025 |
| Dec 20, 2024 | Eric A Adams President & CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +6,250 | $0.00 | $0 | 14,300 | Dec 23, 2024 |
| Dec 20, 2024 | Bryan T Baldasare director | AGrant or award Employee Stock Option (Right to Buy)derivative | +550 | $0.00 | $0 | 975 | Dec 23, 2024 |
| Dec 20, 2024 | Janet P Grove director | AGrant or award Employee Stock Option (Right to Buy)derivative | +550 | $0.00 | $0 | 975 | Dec 23, 2024 |
| Dec 20, 2024 | Eric C Hsu Sr. VP, Pre-Clinical Res/Dev | AGrant or award Employee Stock Option (Right to Buy)derivative | +2,750 | $0.00 | $0 | 5,350 | Dec 23, 2024 |
| Dec 20, 2024 | Andrew Hull director | AGrant or award Employee Stock Option (Right to Buy)derivative | +550 | $0.00 | $0 | 977 | Dec 23, 2024 |
| Dec 20, 2024 | Michael Woudenberg Chief Operating Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +3,750 | $0.00 | $0 | 7,505 | Dec 23, 2024 |
| Dec 20, 2024 | Nicole Lemerond director | AGrant or award Employee Stock Option (Right to Buy)derivative | +550 | $0.00 | $0 | 975 | Dec 23, 2024 |
| Dec 20, 2024 | Netta Jagpal Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +3,750 | $0.00 | $0 | 6,250 | Dec 23, 2024 |
| Dec 20, 2024 | Shane Aaron Johnson Sr VP & General Manager | AGrant or award Employee Stock Option (Right to Buy)derivative | +1,500 | $0.00 | $0 | 3,900 | Dec 23, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Eric A AdamsPresident & CEO
- ADAR1 Capital Management, LLCowner
- Bryan T Baldasaredirector
- Janet P Grovedirector
- Eric C HsuSr. VP, Pre-Clinical Res/Dev
- Andrew Hulldirector
- Netta JagpalChief Financial Officer
- Shane Aaron JohnsonSr VP & General Manager
- Nicole Lemeronddirector
- Michael WoudenbergChief Operating Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.